discontinuation: HDV RNA 431 IU/mL, ALT 70 U/L. HBsAg progres- sively declined from 22 IU/mL at EOT to 0.20 IU/mL at last sampling. In Case 2 and Case 3, BLV treatment was continued for 76 weeks. Both patients achieved and maintained a biochemical and virological response through week 76 with no evidence of virologic break- through or biochemical elevations. At week 76, HDV RNAwas <6 IU/ mL and 150 cp/mL, and ALT 33 and 35 U/L, respectively while no significant changes of HBsAg were observed during treatment. In Case 2, a significant improvement in portal hypertension features and liver function tests were documented, as well as a reduction of plasma cell infiltration and histological activity in the liver biopsy performed at week 72. BLV was well tolerated in all 3 patients, without any clinical drug- related adverse events except for an asymptomatic increase in bile acids. Conclusion: Up to 76 weeks of Bulevirtide 10 mg/day monotherapy is safe and effective in patients with HDV related compensated cirrhosis. SAT418 Correlation between HBV core-related antigen and the new quantitative IGG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure Alessandro Loglio 1 , Floriana Facchetti 1 , Elisa Farina 1 , Nicoletta Nandi 1 , Alberto Perego 2 , Riccardo Perbellini 1 , Sara Colonia Uceda Renteria 3 , Marta Borghi 1 , Roberta Soffredini 1 , Corinna Orsini 2 , Giovanna Lunghi 3 , Ferruccio Ceriotti 3 , Pietro Lampertico 1 . 1 Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, CRC “A.M. and A. Migliavacca” Certer for Liver Disease, Division of Gastroenterologyand Hepatology, Milan, Italy; 2 Fujirebio Italia S.r.l., Pomezia, Italy; 3 Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Virology Unit, Milan, Italy Email: pietro.lampertico@unimi.it Background and Aims: Hepatitis B core-related antigen (HBcrAg) and the quantitative assessment of IgG antibodies against HBV core antigen (qAnti-HBc IgG) are new HBV biomarkers that however have not been compared. The study aimed to assess their relationship in HBsAg positive and negative patients, with and without oral therapy. Method: This cross-sectional/longitudinal retrospective study eval- uated 411 sera from 4 groups of Caucasian patients: Group 1: 189 HBsAg-positive, HBeAg-negative patients under long-term TDF/ETV; Group 2: 28 patients who cleared HBsAg during NUC therapy; Group 3: 87 inactive carriers; Group 4: 22 inactive carriers who cleared HBsAg. qAnti-HBc IgG (Fujirebio) were quantified as cut-off index (COI), and HBcrAg levels (Fujirebio) were expressed as LogU/mL (LLD<2.5 Log U/mL, quantification range 3.0–7.0). Results: In 189 Group 1 patients [age 66, 47% cirrhosis CPTA, 95% gt D, 65% NUC-experienced, TDF/ETV treated for 100 months, undetect- able HBV DNA for 118 months,HBsAg 517 (1–11,781) IU/mL], median qAnti-HBc IgG was 127 (6–282) COI, while HBcrAg 3.0 (2.5–5.3; 56% <LLD) LogU/mL. At multivariate analysis, low qAnti-HBc IgG were associated only with longer HBV DNA suppression (OR 1.02, p< 0.001) while low HBcrAg only with lower qHBsAg. All the 105 HBcrAg negative patients tested positive for qAntiHBc IgG [123 (2–282) COI]. In samples collected afterone year, qAnti-HBc declined from 107 to 85 COI, qHBsAg from 250 to 202 IU/mL, while HBcrAg remained stable (2.8 vs 3.0 LogU/mL; 50%<LLD). The 28 Group 2 patients who cleared HBsAg during NUC [age 59, 36% cirrhosis CPTA] were divided into two subgroups, according to NUC indication (CHB vs recent HBV infection): qAnti-HBc was lower in the former than in the second subgroup [58 (14–222) vs 209 (59–285) COI (p = 0.010)] and HBcrAg 3.0 (2.5–4.1) vs 3.2 (2.6–4.5) LogU/mL, but 59% vs 18% <LLD (p = 0.033), respectively. In Group 3 [age 53, qHBsAg 321 (0.12–52,000) IU/mL], qAnti-HBc were 267 (75–299) COI and HBcrAg 2.7 (2.5–3.9; 76%<LLD); patients with <267 COI had lower qHBsAg and HBV DNA, however only the latter significant (OR 1.00, p = 0.028). In Group 4 (age 64, 27% with anti-HBs) qAnti-HBc were 226 (138–277) COI and HBcrAg 2.8 (95% <LLD). Overall, patients under NUC have both lower qAnti-HBc and HBcrAg level ( p < 0.0001). Conclusion: Anti-HBc IgG and HBcrAg levels are reduced by NUC treatment but have different kinetics, thus representing additional useful markers for the management of HBV patients. SAT419 The establishment of hepatitis B care and treatment clinics with viral load testing capacity in the United Republic of Tanzania: a demonstration project following WHO guidelines, Zanzibar, 2017–2019 Ali Salim 1 , Sanaa Said 1 , Shaun Shadaker 2 , Geoff Beckett 2 , Noele P. Nelson 2 , Brian McMahon 3,4 , Aaron Harris 2 . 1 Mnazi Mmoja Hospital, Zanzibar, Tanzania; 2 Centers for Disease Control and Prevention, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, United States; 3 Alaska Native Tribal Health Consortium, Anchorage, United States; 4 CDC – Arctic Investigations Program, Anchorage, United States Email: ieo9@cdc.gov Background and Aims: In 2015 about 257 million persons were living with chronic hepatitis B worldwide and about 887,000 related deaths occurred. Zanzibar is a low-resource semi-autonomous nation with a hepatitis B prevalence of about 2%. To mitigate this burden, in 2015 the World Health Organization (WHO) issued hepatitis B care and treatment guidelines. We report early results of the implemen- tation of hepatitis B care and treatment programs inZanzibar. Method: A five-year demonstration project was launched December 2016 at Mnazi Mmoja Hospital in Zanzibar. Clinical and laboratory staff at each site received training on the delivery of hepatitis B- directed care and laboratory testing. Participants were recruited from Zanzibar’s National Blood Donation Program where donors are systematically screened for HIV, hepatitis C antibody (anti-HCV), syphilis, and hepatitis B surface antigen (HBsAg). Participants were invited to participate in the program if they tested negative for HIV and anti-HCV, and were HBsAg-positive. Participants were examined for clinical signs of liver disease and received hepatitis B-related laboratory testing every 6–12 months for assessment of treatment eligibility. Specimens were sent to a lab in Dares Salaam for hepatitis B virus (HBV) DNA testing. Tenofovir disoproxil fumarate (TDF) was provided for participants meeting WHO guidelines eligibility. Clinical and laboratory data were collected for programmatic evaluation purposes. Results: After 34 months, 587 participants enrolled: 360 with complete laboratory results, 154 with two clinic visits, and 70 with ≥3 clinic visits. Of those with complete lab results, the median age was 34 years (IQR 28–41), 218 (61%) male. Of these, 26 patients were started on TDF: 17 who met the criteria for liver cirrhosis, and/or 15 with APRI >1.5, 3 met WHO criteria by HBV DNA and ALT; 1 discontinued due to intolerance from fatigue. ALT values decreased among those treated, from a median of 98.5 (IQR 44–246) to 34.5 (IQR 25–62) ( p = 0.06). Of enrolled patients, 1 was diagnosed with hepatocellular carcinoma and 5 patients died due to complications from HBV-associated liver disease. Challenges included patients presenting with advanced liver disease. Conclusion: Hepatitis B care and treatment is feasible in low- resource settings. While challenges remain, testing and linkage to care is critical to decrease the global burden of hepatitis B. SAT420 Nucleos(t)ide analogue therapy decreases the HBeAg loss rate in HBeAg positive chronic hepatitis B patients with hepatitis flare: a propensity score matching study Chien-Wei Peng 1,2 , Rachel Wen-Juei Jeng 1,2 , Yi-Cheng Chen 1,2,3 , Rong-Nan Chien 1,2,3 , Yun-Fan Liaw 2,3 . 1 Chang Gung Memorial Hospital, Linkou branch, Department of Gastroenterology and Hepatology, Taoyuan, Taiwan; 2 Chang Gung University, College of Medicine, Taoyuan, POSTER PRESENTATIONS S862 Journal of Hepatology 2020 vol. 73 | S653–S915